Literature DB >> 20385128

Up-regulation of striatal adenosine A(2A) receptors with iron deficiency in rats: effects on locomotion and cortico-striatal neurotransmission.

César Quiroz1, Virginia Pearson, Seema Gulyani, Richard Allen, Christopher Earley, Sergi Ferré.   

Abstract

Brain iron deficiency leads to altered dopaminergic function in experimental animals, which can provide a mechanistic explanation for iron deficiency-related human sensory-motor disorders, such as Restless Legs Syndrome (RLS). However, mechanisms linking both conditions have not been determined. Considering the strong modulation exerted by adenosine on dopamine signaling, one connection could involve changes in adenosine receptor expression or function. In the striatum, presynaptic A(2A) receptors are localized in glutamatergic terminals contacting GABAergic dynorphinergic neurons and their function can be analyzed by the ability of A(2A) receptor antagonists to block the motor output induced by cortical electrical stimulation. Postsynaptic A(2A) receptors are localized in the dendritic field of GABAergic enkephalinergic neurons and their function can be analyzed by studying the ability of A(2A) receptor antagonists to produce locomotor activity and to counteract striatal ERK1/2 phosphorylation induced by cortical electrical stimulation. Increased density of striatal A(2A) receptors was found in rats fed during 3 weeks with an iron-deficient diet during the post-weaning period. In iron-deficient rats, the selective A(2A) receptor antagonist MSX-3, at doses of 1 and 3 mg/kg, was more effective at blocking motor output induced by cortical electrical stimulation (presynaptic A(2A) receptor-mediated effect) and at enhancing locomotor activation and blocking striatal ERK phosphorylation induced by cortical electrical stimulation (postsynaptic A(2A) receptor-mediated effects). These results indicate that brain iron deficiency induces a functional up-regulation of both striatal pre- and postsynaptic A(2A) receptor, which could be involved in sensory-motor disorders associated with iron deficiency such as RLS. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385128      PMCID: PMC2885550          DOI: 10.1016/j.expneurol.2010.04.004

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  34 in total

1.  Iron deficiency alters dopamine transporter functioning in rat striatum.

Authors:  K M Erikson; B C Jones; J L Beard
Journal:  J Nutr       Date:  2000-11       Impact factor: 4.798

Review 2.  Iron status and neural functioning.

Authors:  John L Beard; James R Connor
Journal:  Annu Rev Nutr       Date:  2003-04-10       Impact factor: 11.848

3.  Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration.

Authors:  Marzena Karcz-Kubicha; Katerina Antoniou; Anton Terasmaa; Davide Quarta; Marcello Solinas; Zuzana Justinova; Antonella Pezzola; Rosaria Reggio; Christa E Müller; Kjell Fuxe; Steven R Goldberg; Patrizia Popoli; Sergi Ferré
Journal:  Neuropsychopharmacology       Date:  2003-04-09       Impact factor: 7.853

4.  Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome.

Authors:  C J Earley; J R Connor; J L Beard; E A Malecki; D K Epstein; R P Allen
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

Review 5.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

Authors:  Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

Review 6.  Iron deficiency alters brain development and functioning.

Authors:  John Beard
Journal:  J Nutr       Date:  2003-05       Impact factor: 4.798

7.  Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome.

Authors:  J R Connor; X S Wang; S M Patton; S L Menzies; J C Troncoso; C J Earley; R P Allen
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

8.  Twenty-four-hour motor activity in human infants with and without iron deficiency anemia.

Authors:  R M Angulo-Kinzler; P Peirano; E Lin; C Algarin; M Garrido; B Lozoff
Journal:  Early Hum Dev       Date:  2002-12       Impact factor: 2.079

9.  D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase.

Authors:  Charles R Gerfen; Shigehiro Miyachi; Ronald Paletzki; Pierre Brown
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

Review 10.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

View more
  13 in total

1.  Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome.

Authors:  César Quiroz; Seema Gulyani; Wan Ruiqian; Jordi Bonaventura; Roy Cutler; Virginia Pearson; Richard P Allen; Christopher J Earley; Mark P Mattson; Sergi Ferré
Journal:  Neuropharmacology       Date:  2016-09-04       Impact factor: 5.250

2.  Targeting hypersensitive corticostriatal terminals in restless legs syndrome.

Authors:  Gabriel Yepes; Xavier Guitart; William Rea; Amy H Newman; Richard P Allen; Christopher J Earley; César Quiroz; Sergi Ferré
Journal:  Ann Neurol       Date:  2017-12-07       Impact factor: 10.422

Review 3.  Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.

Authors:  Christopher J Earley; George R Uhl; Stefan Clemens; Sergi Ferré
Journal:  Sleep Med       Date:  2016-06-27       Impact factor: 3.492

4.  Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice.

Authors:  Mark P DeAndrade; Russell L Johnson; Erica L Unger; Li Zhang; Thomas van Groen; Karen L Gamble; Yuqing Li
Journal:  Hum Mol Genet       Date:  2012-06-07       Impact factor: 6.150

Review 5.  Brain-iron deficiency models of restless legs syndrome.

Authors:  Christopher J Earley; Byron C Jones; Sergi Ferré
Journal:  Exp Neurol       Date:  2022-06-30       Impact factor: 5.620

6.  Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on Δ9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys.

Authors:  Zuzana Justinová; Godfrey H Redhi; Steven R Goldberg; Sergi Ferré
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

7.  Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome.

Authors:  Shangru Lyu; Mark P DeAndrade; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li
Journal:  Behav Brain Res       Date:  2019-07-31       Impact factor: 3.332

8.  Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists.

Authors:  Marco Orru; Jana Bakešová; Marc Brugarolas; César Quiroz; Vahri Beaumont; Steven R Goldberg; Carme Lluís; Antoni Cortés; Rafael Franco; Vicent Casadó; Enric I Canela; Sergi Ferré
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

9.  Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport.

Authors:  Sergi Ferré; César Quiroz; William Rea; Xavier Guitart; Diego García-Borreguero
Journal:  Adv Pharmacol       Date:  2019-01-18

10.  Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome.

Authors:  Sergi Ferré; César Quiroz; Xavier Guitart; William Rea; Arta Seyedian; Estefanía Moreno; Verònica Casadó-Anguera; Manuel Díaz-Ríos; Vicent Casadó; Stefan Clemens; Richard P Allen; Christopher J Earley; Diego García-Borreguero
Journal:  Front Neurosci       Date:  2018-01-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.